Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.

Autor: Aala, Wilson Jr F, Hou, Ping-Chen, Hong, Yi-Kai, Lin, Yu-Chen, Lee, Yu-Rong, Tu, Wei-Ting, Papanikolaou, Marieta, Benzian-Olsson, Natashia, Onoufriadis, Alexandros, Harn, Hans I Chen, Hwang, Daw-Yang, Cheng, Siao Muk, Lu, Kurt, Chen, Peng-Chieh, McGrath, John A, Hsu, Chao-Kai
Předmět:
Zdroj: British Journal of Dermatology; Aug2024, Vol. 191 Issue 2, p252-260, 9p
Abstrakt: Background Dominant dystrophic epidermolysis bullosa (DDEB) is characterized by trauma-induced blisters and, in some individuals, intense pruritus. Precisely what causes itch in DDEB and optimal ways to reduce it have not been fully determined. Objectives To characterize DDEB skin transcriptomes to identify therapeutic targets to reduce pruritus in patients. Methods Using bulk RNA sequencing, we evaluated affected and unaffected skin biopsy samples from six patients with DDEB (all with the very itchy pruriginosa subtype) and four healthy individuals. Single-cell transcriptomes of affected (n = 2) and unaffected (n = 1) DDEB skin and healthy skin (n = 2) were obtained. Dupilumab treatment was provided for three patients. Results The skin bulk transcriptome showed significant enrichment of T helper (Th)1/2 and Th17 pathways in affected DDEB skin compared with nonlesional DDEB skin and healthy skin. Single-cell transcriptomics showed an association of glycolytically active GATA3 + Th2 cells in affected DDEB skin. Treatment with dupilumab in three people with DDEB led to significantly reduced visual analogue scale (VAS) itch scores after 12 weeks (mean VAS 3.83) compared with pretreatment (mean VAS 7.83). Bulk RNAseq and quantitative polymerase chain reaction showed that healthy skin and dupilumab-treated epidermolysis bullosa (EB) pruriginosa skin have similar transcriptomic profiles and reduced Th1/Th2 and Th17 pathway enrichment. Conclusions Single-cell RNAseq helps define an enhanced DDEB-associated Th2 profile and rationalizes drug repurposing of anti-Th2 drugs in treating DDEB pruritus. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index